Hyunwoo (Tony) Kwon, MD PhD

@OhioStatePIIO @mefKjHmuDuTWIfC @Zihai @NatImmunol Congratulations @Zihai and team!

🎉 Congrats to @mefKjHmuDuTWIfC, @Zihai, & team! A remarkable breakthrough: patients with lower ZNF148 expression in #tumor‑infiltrating #CD8⁺ #Tcells consistently show stronger responses to #immunotherapy. Newly published @NatImmunol study uncovers #ZFP148 as a key transcriptional repressor limiting CD8⁺ T‑cell effector differentiation — and highlights its exciting therapeutic potential for boosting antitumor immunity. A huge step forward for cancer immunotherapy. 🚀🧬 nature.com/articles/s4159…

Case report on potential role of combination olaparib and osimetinib after progression on osimetinib with platinum chemotherapy in #EGFR #NSCLC with germline BRCA2 #lcsm @BIDThoracicOnc clinical-lung-cancer.com/article/S1525-…

【Long-term Survival: Nivo+Ipi+Chemo vs Pembro+Chemo in advanced NSCLC】 🇯🇵 RWD (Japan): Multicenter Retrospective Study 💡Nivo+Ipi+Chemo (NICT) demonstrates superior long-term survival over Pembro+Chemo (PCT) in PD-L1 <1% NSCLC 📚Lung Cancer 2026 lungcancerjournal.info/article/S0169-… 🔑Key Results 👥 457 pts with advanced NSCLC treated with NICT or PCT were stratified by PD-L1 (<1% vs ≥1%) with >40 mos follow-up 📈 PD-L1 <1% Cohort: NICT significantly improved OS compared to PCT (Median OS: 47.4 mos vs 16.6 mos; HR 0.50, p=0.007) 🗓 Long-term Benefit: 3-year OS rates in the <1% group favored NICT (51.5% vs 28.2%, p=0.016) ⚖️ PD-L1 ≥1% Cohort: No significant difference in median OS (28.0 vs 28.4 mos) or PFS between regimens ☠️ Safety profiles were comparable (Grade ≥3 TRAEs, discontinuation, and TRD rates), though NICT had higher incidence of skin/pituitary toxicity

#DICIPLE: 4-year 6-month vs continuation Nivo+Ipi in mNSCLC ◼️ PFS: 18.7m vs NR ◼️ OS: 55.5m vs NR ◼️ 18m OS: 80.6% vs 93.8% ◼️ Grade 3-5 irAEs: 54% → 24% ◼️ QoL: 15.5m vs NR (HR=0.36) 🛑 at 6 months = same survival, less toxicity @JTOonline @OncoAlert pubmed.ncbi.nlm.nih.gov/41690366/

First post of #2026 — and the message is clear. EGFR-mutated NSCLC is no longer about choosing the next drug, but about designing the right strategy. #NEJM’s latest editorial crystallizes the shift: from osimertinib monotherapy to biology-driven combinations, informed by resistance mechanisms, toxicity trade-offs, and ctDNA-guided decision making. FLAURA2 and MARIPOSA confirm it: earlier intensification can extend survival — but precision in patient selection now defines good oncology. 2026 starts with a new rule in lung cancer care: strategy > single agent. 🔗 nejm.org/doi/full/10.10… #EGFR #NSCLC #ClinicalPractice Also, appreciate the work by @Larvol for continuously tracking, analyzing, and synthesizing key oncology developments on X. @PTarantinoMD | @DrChoueiri | @YJanjigianMD | @szusmani | @SuyogCancer | @UroDocAsh | @lungoncdoc | @HHorinouchi | @KoheiShitara | @DrYukselUrun | @Erman_Akkus | @VincentRK | @GIcancerDoc | @dr_yakupergun | @kazuki_nozawa | @MamMa_mimumemo | @StephenVLiu | @chulkimMD | @DrRishabhOnco | @TiansterZhang | @NiuSanford | @ArndtVogel | @CJTsaiMDPhD | @ADesaiMD | @End_myeloma | @tompowles1 | @Kenrickng1 | @AndreaNecchi | @RobertoFerrara_ | @_ShankarSiva | @declangmurphy | @Dr_ElvinaA | @montypal | @pashtoonkasi | @neerajaiims | @helops79 | @GIMedOnc | @PGrivasMDPhD | @RahulBanerjeeMD

Really sad for the patients but super cool for science. PD1+CTLA4 induces hyper-progression in renal medullary carcinoma (yes you read that right) mPFS 1.4m. Induced IFNg led to hyper-proliferation in tumor cells Nasty tumor cells! nature.com/articles/s4146…

🚨 New data on seizure prophylaxis in CAR-T! A new study evaluated whether levetiracetam (LVT) prevents ICANS in patients receiving anti-CD19 CAR-T for LBCL. Using a propensity-matched cohort of 254 patients, the findings were clear: 🧠 No reduction in ICANS with LVT prophylaxis • Any-grade ICANS: 32.3% vs 37.1% (ns) • Severe ICANS (G2–4): 15.1% vs 16.1% (ns) 🩸 BUT: LVT was linked to higher early hematotoxicity (ICAHT) • G2–4 ICAHT: 37.3% → 63.9% (P < .001) 📉 No differences in OS, PFS, or non-relapse mortality. 🔍 Takeaway: Routine LVT prophylaxis does not prevent ICANS and may increase toxicity. More work needed to define if/when it should be used. ashpublications.org/bloodadvances/… #CAR_T #ICANS #Lymphoma #HemOnc #Immunotherapy #CellTherapy

🔥🚨#November is 🫁 #LungCancerAwareness Month. Lung Cancer Awareness #SavesLives. Together, WITH #Patients, we keep the #Fight against #LungCancer. We have made a great #Progress but still have a long way to go. #LCAM25 👇🏼Sharing, like every year, my #AWARENESS #Mnemonic

🚨 50 years of progress in NSCLC, beautifully captured in this JTO review! jto.org/article/S1556-… From the pre-cisplatin era to molecular profiling, targeted therapies, ICI, and advances in screening & supportive care. Half a century of lessons, half a century of survival — the true golden age of lung cancer research ✨ @OncoAlert #OncoAlertAF @OncoReporte @myESMO @_SEOM @gecp_org @LungCancerRx @Lung_Cancers

The Chen-Huang Center for EGFR-Mutant Lung Cancers’ webpage was created to offer resources specifically for patients diagnosed with an #EGFR mutation: dana-farber.org/cancer-care/tr… #LCSM #CancerResearch

💨🧬🫁 The mutagenic forces shaping the genomes of lung cancer in never smokers. #LCSM nature.com/articles/s4158…

Clear survival gains in treating lung cancer reflected in this @NEJM article. All pts with lung cancer treated in public hospitals in France show median survival improved from 8.5 months in 2000 to 20.7 months in 2020. No room for nihilism anymore! evidence.nejm.org/doi/full/10.10…

Immensely proud of and grateful for this village! We gathered to celebrate intelligence, integrity, curiosity, and compassion. Congratulations to our graduating ⁦@BIDMC_HOFellows⁩ and thank you to our ⁦⁦BIDMC Heme/Onc family. May your stars shine bright always! ⁦⁦

The best part about @ASCO is gathering with brilliant, kind humans who share a passion and tireless devotion for advancing the well-being and lives of people living with cancer— our @BIDMC_HOFellows are shining stars in that universe! Mentorship + partnership = sustenance.

Excited for the #LCSM session today at #ASCO25! 🚨 Here’s the latest treatment algorithm for advanced/metastatic #NSCLC 👇 How will it change after today?🔥 Can’t wait to see where new agents & trial data may fit in! @LungCancerRx @HemOncFellows @Oncoalert @OncBrothers @n8pennell @SuyogCancer @HemOncFellows @GlopesMd @HHorinouchi @APassaroMD @lungoncdoc @NarjustFlorezMD @DevikaDasMD @DrJNaidoo @NaglaAKarimMD @Lung_Cancers @DrSanjayPopat @tnewsomdavis @Tony_Calles @ns_chd @BalazsHalmosMD @ipreeshagul @BoschBarrera @FordePatrick @LuisRaezMD @COlazagasti @OncNewsCentral @imedverse @Latinamd @Larvol @ChristianRolfo @AboutLungCancer @ilyassahinMD @AEACaP @acmoorephd @DipeshUpretyMD @Alfdoc2 @g_mountzios @marinagarassino @DrRiyazShah @StephenVLiu @weoncologists @M_Torasawa @FawziAbuRous @rajatthawani @thenasheffect @drshieldsmd @BrunaPellini @AnaVManana

🔥🚨@OncoAlert Hot Off The Press Big #NewsRelease by @SMMT_TX in time with #ASCO25 Results from the #HARMONi Phase III global trial evaluating: #Ivonescimab + #Chemo vs #Chemo in pts with advanced #EGFR+ #NSCLC after progression on 3rd gen TKI: ⭐️Statistically significant & clinically meaningful #Improvement in progression-free survival. ✅#PFS HR: 0.52 ✅#OS positive trend : HR 0.79 👇🏻 shorturl.at/COSuW

Thanks @OncLive for this awesome program for fellows! The future of thoracic oncology is bright! #meded #ASCO25 @NarjustFlorezMD @PatelOncology @benlevylungdoc @lungoncdoc @kamarroneMD

A must-read Review on the ever-evolving field of #EGFR mut #NSCLC in@NatRevClinOncol highlighting: ➡️Strategies to improve on 1L 3rd Gen TKI mono therapy ➡️ Ways to tackle resistance post-Osi ➡️Perioperative landscape @LeXiuning @danieltanmd @RamalingamMD @IASLC #LCSM #some

Physician here. If you’ve never had polio or diphtheria or the measles, you can thank vaccines for that.

Consider us if you are looking to join a #HemeOnc community with flexibility in supporting individual-level needs for career development & camaraderie!!#Match2025